Main effects of sodium–glucose cotransporter-2 inhibitors (empaglifozin 10 mg) lupus nephritis
| N | Age/sex | Classification LN (ISN/RPS 2003) | IMS (doses mg/day) | RAASi (doses mg/day) | GFR baseline (mL/min/1.73 m2) | GFR 8 weeks (ml/min/1.73 m2) | Proteinuria baseline (g/day) | Proteinuria 8 weeks (g/day) | Serum albumin baseline (g/dL) | Serum albumin 8 weeks (g/dL) |
| 1 | 63/F | V | S 2.5+MPA 980 | Enalapril 20+SPR 25 | 53 | 44 | 1.8 | 0.9 | 4.2 | 4.1 |
| 2 | 59/F | IIIA | MPA 1600 | Telmisartan 80+SPR 25 | 65 | 60 | 1.9 | 0.8 | 4.2 | 4.5 |
| 3 | 46/F | V | S 2.5+MMF 1250 | Irbesartan 150+SPR 25 | 89 | 74 | 0.62 | 0.27 | 3.9 | 4.3 |
| 4 | 32/F | 1-IVAG+V 2-IVAG | S 5+MPA 720 | Telmisartan 80 | 34 | 30 | 5.96 | 3.7 | 2.7 | 3.5 |
| 5 | 46/F | 1-V 2-IVS (A,C)+V | S 5+MPA 1080 | Enalapril 10+SPR 25 | 94 | 90 | 0.76 | 0.39 | 3.8 | 4.2 |
F, female; GFR, glomerular filtration rate; IMS, immunossupression; LN, lupus nephritis; MMF, mycofenolate mofetil; MPA, mycophenolic acid; RAASi, renin-angiotensin-aldosterone inhibitors; S, steroids; SPR, spironolactone.